
The relevance and impact of Lateral Flow Assays (LFA) as point-of-care devices has been amply demonstrated with the current SARS-CoV-2 pandemic. However, and despite their usefulness, drawbacks like low sensitivity, low specificity, and lack of quantitation are often associated with LFAs. In a paper published in Scientific Reports, Miguel Prazeres from BERG-IST and colleagues from the Indian Institute of Technology (Madras) propose a new LFA architecture that combines nitrocellulose strips with layered cellulose, ZZ-CBM3 fusions and fluorescently labeled Fab fragments. The system was successfully applied to the the quantitative, fluorescence-based detection of the kidney biomarker cystatin C. The work was funded by project CBM-X.